OBJECTIVE: Glioblastoma, the most common and lethal brain tumor, is also one of the most defying forms of malignancies in terms of treatment. Integrated genomic analysis has searched deeper into the molecular architecture of GBM, revealing a new sub-classification and promising precision in the care for patients with specific alterations. METHOD: Here, we present the classification of a Brazilian glioblastoma cohort into its main molecular subtypes. Using a high-throughput DNA sequencing procedure, we have classified this cohort into proneural, classical and mesenchymal sub-types. Next, we tested the possible use of the overexpression of the EGFR and CHI3L1 genes, detected through immunohistochemistry, for the identification of the classical and mesenchymal subtypes, respectively. RESULTS: Our results demonstrate that genetic identification of the glioblastoma subtypes is not possible using single targeted mutations alone, particularly in the case of the Mesenchymal subtype. We also show that it is not possible to single out the mesenchymal cases through CHI3L1 expression. CONCLUSION: Our data indicate that the Mesenchymal subtype, the most malignant of the glioblastomas, needs further and more thorough research to be ensure adequate identification.
resection is very difficult to achieve. The presence of residual tumor cells results in recurrence and malignant progression, albeit at different intervals.
Glioblastomas can be further divided into two subgroups: primary GBMs, which arise de novo, and secondary GBMs, which result from the progression of a lower grade tumor. 3 These two clinical forms of GBM have different and extensively characterized molecular features. 3 The past decade has seen the rise of high-throughput sequencing techniques that provide in-depth knowledge of molecular alterations in tumor cells. GBM has been one of the most molecularly profiled tumors by several groups, including The Cancer Genome Atlas (TCGA) Networks. [4] [5] [6] [7] [8] [9] [10] These studies have singled out specific determinant mutations within the newly identified subtypes: proneural, neural, classical and mesenchymal. Proneural tumors present alterations customized panel included genes such as NF1, RB1, EGFR, TP53, PTEN, IDH1 and PDGFRA, whose alterations have all been previously associated with the three main GBM subtypes: proneural, classical and mesenchymal. Using the SureDesign tool (Agilent Technologies Inc., USA), the targeted RNA capture enrichment baits were designed to include coding exon regions and 50 bp from both the 3' end and 5' end of the flanking intronic sequence. The purpose was to incorporate possible splicing site mutations in our analysis. A total of 973 regions from the 40 genes were targeted for a final capture size of 2.79 Mega base pairs (Mb).
A target-enrichment DNA library was constructed using the Agilent SureSelect XT Target Enrichment Kit (Agilent Technologies Inc.), following the recommended protocol. Two hundred nanograms of tumor DNA was sheared using a E220 focused-ultrasonicator (Covaris, USA) to generate DNA fragments with a mean peak around 150bp. Indexed and adaptor-ligated libraries were multiplexed and paired-end sequenced on Illumina NextSeq 500 platform (Illumina, USA). An additional library was built from peripheral blood DNA from all the patients pooled in equal amounts.
Bioinformatics analysis. Sequencing data was generated as 150-bp paired-end reads using the Illumina Next-Seq platform. Raw data was aligned to the hg38 assembly of the human genome using the BWA mapping software. 12 Aligned reads were coordinate-sorted with the bamsort tool from Biobambam2. 13 Variant calling was performed simultaneously in all the tumor samples with the reference genome-free algorithm Platypus, 14 and in the germline pool with freebayes, with the parameters properly set to call pooled data (pooled-discrete and ploidy parameter set to 132, which corresponds to the number of alleles present in the pool). The resulting VCFs file were annotated with SnpEff and SnpSIFT. 15 Tissue microarray (TMA) construction and Immunohistochemistry. Two representative areas of each tumor were chosen by neuropathologists and marked both on HE sections and on the original paraffin block. Each of the 0.6 mm-diameter three cores of tumor tissue was extracted from the marked area of each donor block using an arraying machine (MTA-1, Beecher Instruments Inc., USA). The cores were inserted into a TMA recipient block in predetermined sites. Sections of 3μm-thickness were cut from the TMA block. A representative TMA section was initially stained with HE to assess the suitability of each core, and all other sections were paraffin coated and stored at -20°C until use.
For immunohistochemical detection, serial TMA sections were deparaffinized, rehydrated, treated for endogenous peroxidase blocking and subjected to antigen retrieval. Slides were immersed in 10 mM citrate buffer, pH 6.0 and incubated at 122°C for 3 min using an electric pressure cooker (BioCare Medical, USA). Specimens were in the IDH1, PDGRFA and TP53 genes; classical tumors display mainly the EGFR mutation/amplification and the presence of the EGFRvIII oncogenic variant; mesenchymal tumors show RB1 and NF1 mutations as their main features. The neural subtype presents overexpression of neural markers, but display no specific genetic alterations. Patient overall survival was also correlated with GBM molecular subtypes, with the mesenchymal subtype presenting the worst prognosis. However, the reproducibility, clinical relevance, and functional basis of these subclasses remain to be established.
In this study, we have developed a NGS-based gene panel to detect and analyze several genes commonly mutated in GBM. We classified a series of Brazilian GBM cases based on the somatic mutation signatures previously established for the three main subtypes: proneural, classical and mesenchymal. We validated our genetic findings through orthogonal methods and immunohistochemistry. In this multi-institution cohort of Brazilian patients, GBM subtype distribution and associated patient outcomes corroborate previously published results and further validates the clinical relevance of GBM subtyping. NGSbased approaches for GBM classification are fast, reliable, and therefore, may have value as a diagnostic tool that may add to the clinical decision-making process.
■ MATERIALS AND METHODS
Included patients and ethical statement. One hundred and nine GBM samples were obtained during therapeutic surgery of patients treated by the Neurosurgery Group of the Department of Neurology at Hospital das Clínicas at the School of Medicine of the University of São Paulo, in the period of 2000 to 2014. Written informed consent was obtained from all patients according to the ethical guidelines approved by the institutional Ethics Committee. (case # 0599/10). Complete patient information, along with the current WHO grading system 1 and clinical findings are presented in Supplemental Table  1 , annexed to this article.
GBM sampling and diagnosis. GBM diagnosis was confirmed by neuropathologists from the Division of Pathological Anatomy of the same institution, according to the WHO grading system available at the time. 11 Samples were macrodissected and immediately snap-frozen in liquid nitrogen upon surgical removal. A 4µm-thick cryosection of each sample was analyzed under a light microscope after hematoxylin-eosin staining for assessment of cellular debris as well as necrotic and non-neoplastic areas; this was followed by removal from the frozen block by microdissection prior to DNA extractions.
Targeted gene panel sequencing. Based on previous literature assessing GBM molecular sub classification, 6,8,9 40 genes were targeted for capture and deep sequencing. This then blocked and further incubated with anti-human CHI3L1 (mouse monoclonal, clone AT4A3; Abcam, United Kingdom) and with anti-human EGFR (mouse monoclonal, clone 31G7; Thermo Fisher Scientific, USA) at 16-20°C for 16 hours. Development of the reaction was performed with a commercial kit (Novolink; Novocastra, United Kingdom) at room temperature, using diaminobenzidine and Harris hematoxylin for nuclear staining. Optimization using positive controls suggested by the manufacturer of each antibody was performed in order to obtain optimal dilution. Two observers (TFG and IFM) evaluated staining intensity of tissue sections independently. A semi-quantitative scoring system considering both intensity of staining and the respective percentage of stained cells was applied as follows: score 0: no cells stained; score 1: 10-25% cells stained; score 2: 26-50% cells stained; score 3: 51-75% cells stained; score 4: 76-100% cells stained. Only cases with positive cell staining with scores ≥ 2 were considered as positive. Digital photomicrographs of representative fields were captured and processed using PICASA 3 (Google, USA).
Statistical analysis. Survival data was assessed by comparing the Kaplan-Meier survival curves using the log-rank (Mantel Cox) test. A p-value < 0.05 was considered statistically significant. For this analysis, we included 77 cases with complete clinical follow-up. Calculations were performed using SPSS, version 23.0 (IBM, USA).
■ RESULTS
Molecular classification of GBM. We used the mutational profile to classify tumors into three major molecular subtypes: proneural, classical, and mesenchymal. We defined the proneural subtype by the presence of IDH1, PDGFRA, and TP53 mutations. The classical subtype was defined by EGFR alterations (amplification and mutations), PTEN mutations, and the presence of the oncogenic variant EGFRVIII. EGFR amplification results was based on a previous publication from our group. 16 Finally, for the definition of the mesenchymal subtype, we used mutations in NF1 and RB1. For each patient, we used DNA from blood leukocytes for germline alteration subtraction. None of the found alteration were present in these germline controls. Aside from this control, we considered in this analysis a) known pathogenic mutations, such as the IDH1 R132H, b) variants that were not present in population databases (1000kg/ExAC), c) variants with predicted pathogenicity (nonsense or frameshift, or a missense mutation with high SIFT and polyphen scores), d) variants not present in our germline pool. All the tumors which did not carry a mutation in the genes described above and met the defined criteria were classified as "others". Given the lack of a specific genetic profile defining the neural subtype, we were not able to identify this subclass in our dataset. The complete list of genetic alteration can be found in Supplemental Table 2 .
The targeted NGS analysis was performed on 109 GBM samples. A 20x coverage was achieved in ~97% of the targeted regions of the GBM samples. The mean coverage of the germline pool was 6063.67x.
Following the proposed criteria, we were able to classify 89 of the 109 analyzed GBM samples within the three major subtypes. Genetic alterations typical of the classical subtype were the most prevalent, accounting for 45.9% of the classified cases. Samples with alterations inherent to the mesenchymal subtype corresponded to 19.3% of the cases; alterations particular to the proneural subtype contributed 16.5% of the cases. This information is diagrammatically shown in Figure 1 . A preview of survival rates are also shown in this figure.
The overall survival of GBM patients according to our molecular classification is shown in Figure 2 : patients classified as mesenchymal GBM had a shorter overall survival in comparison to other subgroups (medians of 8, 9, and 13 months for the mesenchymal, classical, and proneural, respectively; log-rank p < 0.05).
Correlation between molecular classification of GBM and immunohistochemical markers to differentiate between classical and mesenchymal subtypes.
Concomitant with the molecular classification of GBMs, we also assessed the protein expression levels of CHI3L1 (YKL-40) and EGFR. CHI3L1 has been previously associated with the mesenchymal subtype of GBM, while EGFR overexpression is a known characteristic of the classical subtype. Immunohistochemistry staining was performed in a subset of our molecularly classified samples, comprising a cohort of 40 cases (8 mesenchymal, 9 proneural, 20 classical and 3 others). Figure 3 shows the results and Figure 4 depicts examples of stained tissue microarray sections. While only one of the mesenchymal samples showed negative levels of CHI3L1, cases positive for CHI3L1 (scoring above 2) comprised samples of the three subtypes (6 mesenchymal, 6 proneural and 10 classical cases were positive for CHI3L1). For EGFR, all proneural and 6 mesenchymal cases proved to be negative for this marker. Despite presenting genetic characteristics of classical subtypes, 4 of these cases did not present positivity for EGFR immunostaining. A complete listing of immunohistochemistry score can be found in Supplemental Table 2 .
■ DISCUSSION
The advent of next generation sequencing and largescale molecular analysis over the past decade revealed that molecular alterations predict patients' responses to treatment, overall survival and clinical outcome. Each GBM sample, previously classified with the molecular approach, was scored for the classical (EGFR, blue) and mesenchymal (CHI3L1, pink) immunohistochemical markers. Scoring ranged from 0-4, in which score 0: no cells stained; score 1: 10-25% cells stained, score 2: 26-50% cells stained; score 3: 51-75% cells stained; score 4: 76-100% cells stained. EGFR staining was prevalent in classical samples, although classical cases did not present significant staining of the marker, while other mesenchymal samples presented comparable levels of EGFR. CHI3L1 was present in high levels in cases from all three GBM subtypes. and mesenchymal. [4] [5] [6] [7] [8] [9] [10] Their potential to aid the choice of better treatment options is a step forward toward precision medicine.
We have performed a somatic mutation analysis in our GBM cohort utilizing a customized gene panel that comprises all the coding regions and splicing regions the most commonly mutated genes described in GBM. Our NGS panel allowed us to classify approximately ~85% of our samples according to molecular subtype using a single assay; this would have been very laborious and time-consuming using traditional methods, such as Sanger sequencing. 17 The results we obtained, regarding the percentage of each GBM subtype, as well as their association with patient overall survival, is in accordance with what has been published so far. [5] [6] [7] [8] [9] Since the first documentation of the molecular subclasses of GBMs (available by 2010), these have proved
■ CONCLUSION
Our results indicate the need for a genetic approach to further classify GBMs, so that a higher number of patients can profit from the precision provided by such classification in terms of treatment options. 
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CORRELAÇÃO ENTRE AS CARACTERÍSTICAS MOLECULARES E OS SUBTIPOS GENÉTICOS DOS GLIOBLASTOMAS: ANÁLISE CRÍTICA DE 109 CASOS
OBJETIVO: O glioblastoma (GBM), o tumor cerebral mais comum e mais letal, é também um dos tipos de tumores de mais difícil tratamento. Análises genômicas integradas têm contribuído para um melhor entendimento to be fundamental for new discoveries that may ultimately lead to better clinical approaches and precision medicine. For instance, Davis et al 18 used the classification to compare genetic alterations in cultured brain-tumor initiating cells. This model system is important to study treatment options and GBM biology. Natash et al 19 explored the role of oncostatin, a cytokine present in the microenvironment of GBM and its signaling pathway, which is associated with poor prognosis. They related such features to the aggressive nature in the mesenchymal GBM subtype. Chen and Xu 20 have recently developed an algorithm that matches FDA approved drugs to the molecular subtype of GBMs, based on the genetic alterations of each subtype. Thus, it is important to specifically differentiate classical from mesenchymal GBMs: classical GBMs are amenable to treatment by specific tyrosine kinase inhibitors and adjuvant antibodies; 21 in contrast, mesenchymal GBMs have only one potentially useful drug, currently introduced as a phase 1 clinical trial (clinical trial identifier: NCT02272270). Therefore, new practical proposals, more suitable for major diagnostic centers, have been looked for. The exemplified studies highlight the usefulness of GBM classification in improving current knowledge, biological understanding and diagnosis and treatment options for this tumor.
However, and because the basis for such classification is the genetic approach, requiring the implementation of molecular biology techniques, other more feasible methodologies have been searched for. A recent study revealed that MRI derived quantitative volumetric tumor phenotype features only moderately predict the molecular GBM subtypes, suggesting that subtypes do not generally alter the size composition of tumor areas. 22 Therefore, the more doable proteomic IHC-based approach, still based on the reported molecular findings, has been the preferred technique for patient classification.
Both proneural and classical GBM subtypes present genetic point mutations or alterations (IDH1 R132H and EGFRvIII, respectively) that have made it possible to develop, over recent years, specific antibodies to achieve a cheaper and more suitable approach in major diagnostic centers. 23, 24 Nonetheless, the alteration of EGFRvIII was found in only 28.4% of our GBM cohort, while classical cases corresponded to 45.9% of all cases. For those extra cases, EGFR protein overexpression still excluded 4 out of 23 samples with a classical genetic subtype.
The mesenchymal subtype presents a high level of heterogeneity of alterations within the usually mutated genes of this subtype (NF1 and RB1). CHI3L1 (also known as YKL-40) is a secreted lectin, related to the regulation of hypoxia-induced injury response and has been previously associated with the mesenchymal GBM. 6, 8 Previous studies have proposed CHI3L1 as an additional marker to be used as a diagnosis tool through an immunohistochemical approach for the sub classification of GBMs. 25, 26 Yet, our 
